Computational De Novo Design of Miniprotein Candidate Neutralizers Targeting the IL-23 Cytokine Subunit p19
Organizations: Department of Computer Science, University of Maryland, College Park, MD, USA
Abstract
Interleukin-23 (IL-23) drives T-helper-17 inflammation underlying inflammatory bowel disease and psoriasis; anti-p19 antibodies are clinically effective but large, costly, and injectable. De novo miniproteins are an attractive alternative, yet published designs target the IL-23 receptor; the IL-23 cytokine itself has not been addressed. A further obstacle is that the standard confidence score (ipTM) tracks construct length rather than interface quality. We computationally design miniprotein binders against the IL-23R-binding face of p19 (PDB 3DUH) and score every design with ipSAE, a length-robust interface metric derived from AlphaFold-initial-guess predicted aligned error. A conventional RFdiffusion/ProteinMPNN/ColabFold pipeline yields no reliable predicted interface across 972 designs (best ipSAE 0.30), and a scoring artifact, in which single-sequence ColabFold under-rates binder pLDDT by approximately 56 points, explains an earlier misleading "binders do not fold" signal. An interface-optimized hallucination method (BindCraft), scored identically, yields 42 of 50 designs above ipSAE 0.60 (best 0.804). An AlphaFold-independent geometric check reproduces the conventional failure: no top-ranked conventional design reaches the buried area or interface hydrogen-bond count of the weakest lead. Five all-alpha-helical leads (72-104 residues) collectively engage all six targeted hotspots; two dock within the intact p40/p19 heterodimer and all show favorable Rosetta energetics. A p40-alone counter-screen returns ipSAE 0.00 for all five, indicating no spurious p40 interface. To our knowledge, these are the first computationally proposed de novo miniprotein candidates designed to occlude the IL-23R-binding face of IL-23 p19. All results require experimental validation.
Figures & tables
| Conventional | BindCraft | |
|---|---|---|
| Metric | ( ) | leads ( ) |
| dSASA (Å 2 ) | 1149 (144–1755) | 2204–3018 |
| Shape compl. | 0.44 (0.07–0.70) | 0.62–0.69 |
| Interface H-bonds | 0 (0–3) | 3.5–10.5 |
| Meets all three | 0/20 | 5/5 |
| ipSAE cutoff | Conventional ( ) | BindCraft ( ) |
|---|---|---|
| 0.50 | 0 | 45 |
| 0.60 | 0 | 42 |
| 0.70 | 0 | 38 |
| 0.80 | 0 | 2 |
| # | Design | Regime | Len | ipSAE | minPAE (Å) | RMSD (Å) | Hotspots (n/6) | %Hel | G (REU) | dSASA | SC | HB | Cont. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | l94_s482991_mpnn8 | p19-only | 94 | 0.804 | 0.94 | 1.69 | 51,80,81,89 (4) | 91 | 2204 | 0.68 | 3.5 | 35 | |
| 2 | l104_s309115_mpnn6 | p19-only | 104 | 0.801 | 0.99 | 1.50 | 51,137,140 (3) | 91 | 2962 | 0.69 | 10.5 | 34 | |
| 3 | l72_s467308_mpnn8 | p19-only | 72 | 0.785 | 0.92 | 1.37 | 80,81,89 (3) | 88 | -87.3 | 3018 | 0.68 | 8.5 | 39 |
| 4 | l92_s675453_mpnn18 | full | 92 | 0.789 | 1.05 | 3.17 | 51,80,81,89,137 (5) | 78 | 2960 | 0.62 | 9.5 | 28 | |
| 5 | l83_s957191_mpnn2 | full | 83 | 0.763 | 1.12 | 1.86 | 51,80,81,89 (4) | 81 | 2943 | 0.67 | 9.0 | 22 |
| Lead | ipSAE (p19) | ipSAE (p40) | ipTM (p40) |
|---|---|---|---|
| l94 | 0.804 | 0.00 | 0.12 |
| l104 | 0.801 | 0.00 | 0.12 |
| l72 | 0.785 | 0.00 | 0.11 |
| l92 | 0.789 | 0.00 | 0.12 |
| l83 | 0.763 | 0.00 | 0.12 |
Protein Binder Design
Protein binder design creates proteins, antibodies, and peptides that bind selected molecular targets with desired specificity and function.
See all 23 papers